key: cord-0941055-cye0wxje authors: Wang, Michael T.M.; Niederer, Rachael L.; McGhee, Charles N.J.; Danesh-Meyer, Helen V. title: COVID-19 vaccination and the eye date: 2022-02-25 journal: Am J Ophthalmol DOI: 10.1016/j.ajo.2022.02.011 sha: 548b37de655467964bbc1f91d71a77b64e706ec4 doc_id: 941055 cord_uid: cye0wxje Purpose To summarize the current evidence on COVID-19 vaccine-associated ocular adverse events. Design Narrative literature review. Methods The literature search was conducted in August 2021 using four electronic databases (MEDLINE, EMBASE, PubMed, and the Cochrane Database of Systematic Reviews), and population-based pharmacovigilance surveillance data were retrieved from all governmental agencies participating in the World Health Organization (WHO) Programme for International Drug Monitoring with publicly available online adverse event databases in English. Results A small number of case reports have documented uveitis flares and acute corneal graft rejection occurring within the first three weeks following immunisation, while isolated cases of optic neuropathies, retinal conditions, scleritis, and herpetic eye disease have also been highlighted. However, data from population-based pharmacovigilance surveillance systems would suggest that the prevalence of vaccination-associated ocular adverse events are very rare. Conclusions Vaccination-associated ocular adverse events are rare, and there is currently no substantive evidence to counterweigh the overwhelming benefits of COVID-19 immunisation in patients with pre-existing ophthalmic conditions. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in December 2019 led to the devastating coronavirus disease 2019 (COVID- 19) pandemic, which has emerged to become one of the largest global health threats to date. [1] [2] [3] Almost 220 million people have been infected worldwide as of late August 2021, and more than 4.5 million lives claimed. 2 However, the isolation of the SARS-CoV-2 virus and the subsequent publication of its genome sequence in January 2020 ignited an unprecedented global response towards the accelerated development of preventative vaccine candidates, and mobilized multinational collaborative efforts between pharmaceutical corporations, academic institutions, and governmental agencies. 4, 5 The expedited process culminated in two recombinant mRNA vaccines (Pfizer/ BioNTech BNT162b2, and Moderna mRNA-1273) being granted emergency use authorization by the United States Food and Drug Administration (FDA) in December 2020. 6 A number of other immunisations, including two adenovirus vector-based vaccines (AstraZeneca ChAdOx1 nCoV-19, and Janssen Ad26.COV2.S), 6 have subsequently been approved worldwide, and more than 5.3 billion COVID-19 vaccination doses have been administered globally to date. 2 Large phase III clinical trials have confirmed the high protective efficacy levels of several approved vaccines against serious COVID-19 infection, as well as demonstrating favourable safety profiles and low incidence rates of major adverse events. [7] [8] [9] [10] Nevertheless, the inherent methodological limitations of phase III clinical trials, including sample size, follow-up duration, and enrolment criteria restrictions, would preclude dedicated evaluation of rare and serious adverse vaccine-associated outcomes. 11 Population-based pharmacovigilance surveillance systems have therefore become necessary to allow for ongoing monitoring of vaccine safety. 11, 12 A number of rare systemic adverse events following COVID-19 immunisation have since garnered considerable attention, including cerebral venous thrombosis, immune thrombocytopenia and acute myocarditis. [13] [14] [15] However, there remains significant paucity of scientific evidence evaluating the potential adverse effects of COVID-19 vaccines to the eye. 16 The purpose of this narrative literature review was therefore to provide an overview of the current evidence on COVID-19 vaccineassociated ocular adverse events, as well as the clinical safety in patients with preexisting ophthalmic conditions, using population-based pharmacovigilance surveillance systems and data reported in the peer-reviewed literature. Population-based pharmacovigilance surveillance data were retrieved through searching the websites of all governmental agencies participating in the World Health Organization (WHO) Programme for International Drug Monitoring with publicly available online adverse event databases in English ( Figure 2 ). 17 Vaccineassociated adverse event data were extracted from the government agency websites on August 31, 2021, including the Australia Therapeutic Goods Administration Database of Adverse Event Notifications (DAEN), 18 the Canada Vigilance Adverse Reaction Database, 19 the European Union Medicines Agency EudraVigilance System, 20 the United Kingdom Medicines and Healthcare Products Regulatory Agency, 21 and the United States Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS). 22 The number of ocular adverse events occurring following administration of each type of vaccine was recorded. Data on vaccination dose administration were retrieved from the University of Oxford Our World in Data website on August 31, 2021, which is compiled from official reports released by national public health agencies. 2 Prevalence rates of ocular adverse events were calculated by dividing the number of events by the number of vaccine doses administered. A summary of population-based pharmacovigilance surveillance data is provided in Table 2 . It is acknowledged that data generated from populationbased pharmacovigilance surveillance systems can be subjected to bias secondary to the unverified nature of suspected adverse event reporting conducted by individual clinicians and patients, and causal relationships and direct association cannot therefore be inferred. COVID-19 vaccine-associated uveitis has been reported in 27 cases in the peerreviewed literature to date (Table 1) , with onset ranging from 1 to 30 days following vaccine administration. [23] [24] [25] [26] [27] Twenty-five of the 27 cases received the recombinant mRNA BNT162b2 (Pfizer/ BioNTech) vaccine, while the remaining 2 cases received the adenovirus vector ChAdOx1 nCoV-19 (AstraZeneca) and inactivated virus BBIBP-CorV (Sinopharm) vaccines, respectively. Seventeen cases developed uveitis following the second dose, eight cases following the first dose, while dose administration details were not available for the remaining two cases. Eight patients had a history of previous uveitis, nine patients had a background of autoimmune rheumatologic disease, while 12 patients had no previous history of ocular or systemic inflammatory conditions. Human leukocyte antigen B27 (HLA-B27) testing was negative in 1 case, and results unavailable in all remaining 26 cases. Of the 25 cases with available clinical data, 20 patients had isolated anterior uveitis, 2 patients had multiple evanescent white dot syndrome (MEWDS), 1 patient had anterior and intermediate uveitis with cystoid macular oedema, 1 patient had multifocal choroiditis, and 1 patient had panuveitis. Complete resolution of the uveitis flare and/or recovery to baseline visual acuity was achieved in all 22 patients treated with topical, intravitreal, and/or systemic corticosteroid therapy, while the 2 patients with MEWDS were managed conservatively and demonstrated significant improvement with recovery to baseline visual acuity at final follow-up. Clinical follow-up details were not documented for the 3 remaining uveitis cases. A single case of Vogt-Koyanagi-Harada disease reactivation was reported to occur in a patient six weeks after receiving the second dose of the BNT162b2 (Pfizer/ BioNTech) vaccine, with significant anterior segment inflammation, retinal folds, and subretinal fluid. 28 The patient had previously been well controlled on maintenance treatment with infliximab administration every 10 weeks for the past 6 years. Clinical improvements of the reactivation occurred following a five-day course of high dose corticosteroid therapy and infliximab administration. A small case series study reported two cases of post-vaccination acute scleritis and one case of episcleritis within 15 days of inactivated virus BBIBP-CorV (Sinopharm) vaccine administration. 29 Clinical follow-up details were provided for only one of the post-vaccination scleritis cases, and resolution was reported to occur following a one week tapering course of topical corticosteroid drops, with no requirement for systemic corticosteroid therapy. Although the coincidental occurrence of uveitis or scleritis following immunisation could not be completely excluded in the reported cases, the possibility for the COVID-19 vaccine to trigger or exacerbate ocular inflammatory disease is not inconceivable given the close temporal association and lack of other explanatory factors. Moreover, vaccine-associated uveitis has also been previously documented to occur following administration of other types of immunisations, with a recent review identifying 289 cases of vaccine-associated uveitis being reported in the literature between 1984 to 2014. 30 A wide range of immunisations have been reported to trigger uveitis flares, including hepatitis A and B, human papillomavirus (HPV), influenza, Bacillus Calmette-Guérin (BCG), measles-mumps-rubella (MMR), and varicella zoster. 30 However, the pathophysiology underlying vaccine-associated ocular inflammatory disease remains yet to be fully understood, and a myriad of potential mechanisms have been hypothesised, including molecular mimicry between peptide fragments of the vaccine and host antigens, delayed-type hypersensitivity and immune complex deposition, as well as immune responses generated against adjuvants within the vaccine. 26, 30 Population-based adverse event reporting data show that the prevalence rates of COVID-19 vaccine-associated uveitis were 0.9 cases per million doses or less, while scleritis occurred in 0.2 cases per million doses or less, and episcleritis occurred in 0.3 cases per million doses or less (Table 2) . [18] [19] [20] [21] [22] In addition, a multicentre observational study comparing recombinant mRNA BNT162b2 (Pfizer/ BioNTech) vaccine administration in 686 patients with autoimmune inflammatory rheumatic diseases and 121 healthy controls showed that uveitis occurred in 2 (0.3%) patients with systemic autoimmune conditions and 0 (0.0%) of healthy controls. 23 On balance of the currently available evidence, patients with pre-existing ocular inflammatory conditions should not be discouraged from receiving COVID-19 vaccination, particularly given that the high protective efficacy against severe infection would likely outweigh the relatively low risk of triggering a uveitis flare. Moreover, complete resolution or significant improvement were also observed in all case reports with timely commencement of standard treatment protocols. [24] [25] [26] 29 There is currently insufficient evidence to support prophylactic treatment in patients with pre-existing ocular inflammatory conditions following immunisation. However, patients with a background of systemic autoimmune disease or previous uveitis could be counselled regarding the potential symptoms associated with vaccineassociated uveitis, particularly given that early recognition and treatment can yield favourable outcomes. Three cases of first-episode herpes zoster ophthalmicus, occurring within four days to one week following COVID-19 vaccine administration, have been reported in the peer-reviewed literature (Table 1) . 31, 32 The cases were reported after receiving the first dose of the recombinant mRNA-1273 (Moderna) and BNT162b2 (Pfizer/ BioNTech), and the adenovirus vector Ad26.COV2.S (Janssen) vaccines, respectively. Ophthalmic involvement was limited to conjunctivitis in two cases, while no ophthalmic involvement was reported in the third case, and resolution was achieved in all cases with routine systemic antiviral treatment. Although causality could not be inferred on the basis of isolated case reports, the potential for vaccineinduced immunomodulation is not inconceivable with previous cases of herpes zoster reactivation being reported following the administration of the trivalent influenza, hepatitis A, and rabies vaccinations. 33 An isolated case of herpes simplex stromal keratitis recurrence was reported to occur in a patient one day after receiving the first dose of the adenovirus vector ChAdOx1 nCoV-19 (AstraZeneca) vaccine. 34 The patient had a history of herpes simplex keratitis 40 years previously. Clinical improvements were observed with systemic antiviral and topical corticosteroid therapy, although some residual corneal scarring developed. Data from adverse event reporting systems show that the population prevalence rates of post-vaccination ophthalmic herpes zoster were 0.5 cases per million doses or lower, and the rates of ophthalmic herpes simplex were 0.05 cases per million doses or lower ( Table 2) . [18] [19] [20] [21] [22] Overall, the very low rates of post-vaccination ophthalmic herpes zoster and simplex would suggest that there is no substantive evidence to support the requirement for prophylactic antiviral treatment for patients with previous herpetic eye disease undergoing COVID-19 immunisation. There have been seven reported cases of acute corneal graft rejection, occurring between four days to three weeks following COVID-19 vaccine administration, in the peer-reviewed literature (Table 1) . [35] [36] [37] [38] [39] [40] Four of the cases occurred in patients with penetrating keratoplasty (PKP), while the three remaining patients had Descemet membrane endothelial keratoplasty (DMEK). Two of the cases with PKP were regrafts, with one patient having late endothelial failure following the first PKP graft for keratoconus, while the other patient had a previous failed Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) for Fuchs' endothelial dystrophy, and no other pre-existing risk factors for corneal graft rejection were documented. Six of the seven cases of graft rejection were reported following recombinant mRNA BNT162b2 (Pfizer/ BioNTech) vaccine administration, while the remaining case occurred after adenovirus vector ChAdOx1 nCoV-19 (AstraZeneca) vaccine administration. With the exception of one case being reported following the second vaccine dose, graft rejection occurred after the first dose in all six remaining patients. Favourable treatment outcomes with resolution of the rejection episode and prevention of graft failure were achieved by timely commencement of intensive topical and/or systemic corticosteroid therapy in all six cases with recorded clinical follow-up. It is acknowledged that causality and direct association cannot be inferred on the basis of case reports, and the potential for coincidental occurrence cannot be completely excluded. However, the close temporal association and lack of other precipitating factors in all seven cases would warrant judicious interpretation. The potential pathophysiological mechanisms underlying vaccine-associated corneal graft rejection remains poorly understood, although rare cases of acute rejection have also been previously reported to occur following hepatitis B, influenza, yellow fever, and tetanus toxoid vaccination. [41] [42] [43] Approved COVID-19 vaccines have generally been shown to elicit strong adaptive humoral and cellular immune reactions, including high levels of neutralising antibody titres and Th1-type CD4+ lymphocytic responses. 44 In particular, the Th1-type CD4+ lymphocytes have been demonstrated to be among the primary mediators of corneal graft rejection, 45 however, it remains uncertain whether the development of cellular antigen crossreactivity or nonspecific immune activation might have contributed to the reported cases of vaccine-associated rejection. 36, 39 Data from population-based adverse event reporting systems show that postvaccination corneal graft rejection rates were 0.1 cases per million doses or lower ( Table 2) . [18] [19] [20] [21] [22] However, it is acknowledged that these databases did not record the total number of corneal graft recipients that had received vaccination doses, and that the calculation of prevalence rates were conducted using the total number of vaccination doses administered in the general population. Nevertheless, the low overall population prevalence rates would appear to be consistent with the limited 9 number of case reports in the peer-reviewed literature, although the potential influence of reporting and publication bias is acknowledged. Corneal graft recipients should therefore not be deterred from receiving COVID-19 vaccines, particularly given that the overwhelming benefits will likely outweigh the relatively low risk of graft rejection. Moreover, favourable treatment outcomes were achieved with timely commencement of topical or systemic corticosteroid therapy in all reported cases of vaccine-associated graft rejection with documented clinical follow-up. [35] [36] [37] 39 There is currently insufficient evidence to suggest the need for delaying non-urgent corneal graft operations following vaccination administration. Nevertheless, it would remain prudent for eye care practitioners to counsel graft recipients to seek prompt review for ocular discomfort or visual decline following vaccination. In addition, the potential for under-reporting of vaccine-associated graft rejection in the peer-reviewed literature and population-based pharmacovigilance systems cannot be completely excluded. Although there is currently no evidence to support the efficacy of routine prophylactic uptitration of topical corticosteroid therapy in preventing vaccine-associated corneal graft rejection, these treatment measures might be prudently considered in high risk corneal transplant patients undergoing COVID-19 immunisation. 46 A few cases of post-vaccination retinal disease have been reported in the peerreviewed literature, including six cases of acute macular neuroretinopathy, one case of paracentral acute middle maculopathy, and one case of subretinal fluid thought to represent forme fruste central serous chorioretinopathy (Table 1) . 29, [47] [48] [49] All cases were documented to occur within 3 to 15 days following immunisation. Four of the acute macular neuroretinopathy cases developed following administration of the adenovirus vector ChAdOx1 nCoV-19 (AstraZeneca) vaccine, while the remaining cases of macular pathology occurred following administration of the inactivated virus BBIBP-CorV (Sinopharm) vaccine. Clinical follow-up details was provided for only one of the cases with acute macular neuroretinopathy, and the optical coherence tomographic lesions were reported to resolve spontaneously at two months. Nevertheless, it was acknowledged that causality and association could not be reliably determined in the context of the typically idiopathic nature of acute macular neuroretinopathy, 47 and further clinical details were not provided for the cases presenting with post-vaccination paracentral acute middle maculopathy and subretinal fluid. There have been no reported cases of COVID-19 vaccineassociated adverse events in patients with age-related macular degeneration in the peer-reviewed literature to date. A single isolated case of acute zonal occult outer retinopathy was reported to occur 10 days following receiving the second dose of the recombinant mRNA-1273 (Moderna) vaccine. 50 The patient was treated with an intravitreal dexamethasone implant, and combination azathioprine and cyclosporine therapy was considered, although further clinical follow-up details were not documented. It remains unclear whether cross-reactivity of the vaccination-generated neutralising antibodies or Th1type CD4+ lymphocytic response to the proteins and antigens in the outer retinal layers and retinal pigment epithelium might have contributed in the setting of the close temporal association. 50 Population-based adverse event reporting systems show that vaccination-associated retinal conditions are rare, with occurrence rates being 0.3 cases per million doses or less ( Table 2) . [18] [19] [20] [21] [22] The low population prevalence rates and isolated case reports in the peer-reviewed literature would suggest that there is insufficient evidence to indicate the requirement for prophylactic treatment or delaying immunisation in patients with pre-existing retinal conditions at this juncture. Two cases of COVID-19 vaccine-associated optic neuritis have been reported in the peer-reviewed literature to date (Table 1) . 51, 52 The first case occurred in a patient with longstanding relapsing-remittent multiple sclerosis (MS), who developed severe bilateral optic neuritis with chiasmal involvement and longitudinal extensive transverse myelitis, resembling neuromyelitis optica spectrum disorder (NMOSD), two weeks following receiving the first dose of the adenovirus vector ChAdOx1 nCoV-19 (AstraZeneca) vaccine. 51 The patient had previously been treated with natalizumab for 10 years, with the last dose received 8 days before immunisation. Prior to receiving the vaccination, the patient had not previously demonstrated clinical or radiological evidence of NMOSD or optic neuritis. Subsequent neuronal autoantibody testing was negative for aquaporin-4 (AQP4), myelin oligodendrocyte glycoprotein (MOG), glial fibrillary acid protein (GFAP), and flotillin. The patient was treated with high dose systemic corticosteroids, plasmapheresis and immunoadsorption, and achieved mild improvement in visual acuities with recognition of motion but not objects. However, there was persistence of paraplegia, loss of sensory function below T5, and incontinence at 2 months. Overall, the onset of symptoms two weeks following immunisation could potentially be consistent with a dysimmunological process, although it remains uncertain whether this might have been partially attributed to the intended B lymphocyte response targeting the adenovirus vector vaccine, or further exacerbated by the activation and accumulation of B lymphocytes in the peripheral blood incited by natalizumab. 51, 53 The second case occurred in a patient who developed MOG antibody-associated bilateral anterior optic neuritis and concurrent subacute thyroiditis, with symptom onset 6 weeks following the first dose and 12 hours after receiving the second dose of the inactivated virus CoronaVac (Sinovac) vaccine. 52 The patient was examined 5 days following symptom onset and demonstrated bilateral optic disc swelling, positive anti-MOG IgG, elevated thyroid stimulating hormone (TSH), antithyroglobluin, anti-thyroid peroxidase, but normal thyroxine levels. Magnetic resonance imaging (MRI) and lumbar puncture assessment ruled out intracranial hypertension, tumour, and demyelinating disease. The patient was treated with five days of intravenous methylprednisolone followed by oral corticosteroid taper, and demonstrated improvements in optic disc swelling, recovery of visual acuity and fields to baseline levels, and normalisation of thyroid function within one week. In the absence of previous anti-MOG IgG testing, it is difficult to distinguish whether the case represented vaccine-associated or coincidental first manifestation of MOG antibody disorder. However, the possibility of vaccine-associated disease is not inconceivable, with a previous reported case of transient anti-MOG IgG seropositivity following multiple vaccinations for tetanus toxoid, measles-mumps-rubella (MMR), and varicella zoster, 54 as well as a number of cases of concurrent MOG antibodyassociated optic neuritis with COVID-19 infection. [55] [56] [57] In addition, temporal artery biopsy-positive bilateral arteritic anterior ischemic optic neuropathy (AAION) was reported to occur in a single case, with symptom onset occurring two days following the second dose of the recombinant mRNA BNT162b2 (Pfizer/ BioNTech) vaccine. 50 The patient had no previous personal or family history of autoimmune disease, and presented for medical review 35 days following initial vision loss. High dose oral corticosteroid therapy and subcutaneous tocilizumab therapy was commenced, although further clinical follow-up was not documented. The possibility of coincidental disease cannot be discounted, and causation and association cannot be inferred solely on the absence of other precipitating factors. However, the close temporal association between immunisation and the onset of autoimmune disease might lend limited support towards the potential contribution of cross-reactivity of the vaccine-generated neutralizing antibodies and/or the Th1-type CD4+ lymphocytic responses towards antigens and proteins expressed in large arteries. 50, 58 Moreover, a previous case of giant cell arteritis has also been reported to occur with close temporal association to the administration of the influenza vaccine. 58 There have been no reported cases of adverse effects associated with COVID-19 vaccination in patients with glaucoma in the peer-reviewed literature to date. Population-based pharmacovigilance reporting shows that post-vaccination optic nerve disorders are relatively rare, with occurrence rates of 1 case per million doses or less (Table 2) . [18] [19] [20] [21] [22] Overall, in the context of only three isolated cases of vaccineassociated optic neuropathies in the peer-reviewed literature, as well as the low reported population-based prevalence rates, there is insufficient evidence to mandate prophylactic therapy or delaying immunisation in patients with existing optic nerve disorders, although counselling to seek prompt medical attention for visual decline following vaccination would be prudent. Two cases of COVID-19 vaccine-induced immune thrombotic thrombocytopenia (VITTP) with superior ophthalmic vein thrombosis have been reported to date. 59, 60 Both cases occurred 10 days following the administration of the first dose of the adenovirus vector ChAdOx1 nCoV-19 (AstraZeneca) vaccine, and in patients with no previous history of autoimmune or thromboembolic conditions. In the first case, the patient presented with severe headache, orbital swelling, proptosis, reduced visual acuity, limited ocular motility, and diplopia. Investigations demonstrated thrombocytopenia, elevated D-dimer levels, and high antibody levels against the platelet factor 4/polyanion complexes, and contrast-enhanced MRI revealed a left superior ophthalmic vein thrombosis. The patient was treated with a two-day course of intravenous immunoglobulin followed by a tapering course of oral corticosteroid therapy, and commenced on rivaroxaban anticoagulation. Symptomatic resolution occurred within 5 days, platelet levels normalised within 1 week, and D-dimer levels normalised within 2 weeks. In the second case, the patient presented with retroorbital pain, conjunctival injection, retro-orbital pain, and diplopia. Laboratory investigations showed thrombocytopenia with high antibody levels against the platelet factor 4/polyanion complexes, while contrast-enhance MRI demonstrated bilateral superior ophthalmic vein thrombosis. The patient was treated with intravenous dexamethasone and heparin, but subsequently developed a left parietal lobe ischemic stroke 8 days following admission. The underlying causes of VITTP and secondary thrombosis is not fully understood, but is thought to involve the generation of neoantigens by the binding of vaccine components with platelet factor 4. [61] [62] [63] [64] Antibodies are then generated against these neoantigens that can induce pancellular activation, involving platelets, coagulation pathways, monocytes, neutrophils, and endothelial cells, which contributes to significantly elevated thrombotic risk. [61] [62] [63] [64] A single case of isolated abducens nerve palsy was reported to occur in a patient two days after receiving the recombinant mRNA BNT162b2 (Pfizer/ BioNTech) vaccine. 65 The report did not specify whether this was the first or second vaccination dose. MRI with gadolinium of the brain and orbits demonstrated no cause, and subsequent follow-up clinical details were not provided. Although it is acknowledged that causality cannot be inferred on the basis of a single case report, the potential for vaccine-associated abducens nerve palsy is not inconceivable with previous cases being reported to occur following the administration of the diphtheria-pertussistetanus (DPT), measles-mumps-rubella (MMR), hepatitis B, and influenza vaccines. [66] [67] [68] [69] [70] The pathophysiological mechanisms underlying post-vaccination ocular nerve palsies remains unknown, but have been hypothesised to involve immune-mediated demyelination or localised vasculitis. [66] [67] [68] [69] [70] There have been six case reports in the peer-reviewed literature of Bell's palsy occurring between two days to four weeks following COVID-19 vaccine administration (Table 1) , including four cases of unilateral Bell's palsy and two cases of bilateral sequential Bell's palsy. [71] [72] [73] [74] [75] [76] Three of the six cases were reported following recombinant mRNA BNT162b2 (Pfizer/ BioNTech) vaccine administration, and the other three cases occurred following mRNA-1273 (Moderna) vaccine administration. Two of the cases occurred following the first vaccine dose, and two cases occurred following the second dose. In one patient with bilateral sequential Bell's palsy, the two episodes occurred following the first and second vaccine doses, respectively. Dose details were not available for the remaining two patients. Full resolution or significant clinical improvement with steroid therapy were reported in all cases where follow-up details were provided. The potential association between COVD-19 vaccination and Bell's palsy has been further investigated in a number of observational studies. One retrospective crosssectional study surveyed participants regarding adverse events occurring following two doses of the BNT162b2 (Pfizer/ BioNTech) vaccine, and 3 of 299 (1%) participants reported Bell's palsy following the first dose, while 0 of 156 (0%) participants reported Bell's palsy following the second dose. 77 The study concluded that Bell's palsy was a rare adverse event, although the absence of a control group, lack of reporting of timing post-vaccination, and the potential for recall bias were acknowledged. Another study reported that 21 of 37 patients (56.8%) admitted for Bell's palsy during a two-month period had been administered the first or second dose of the BNT162b2 (Pfizer/ BioNTech) vaccine within the previous four weeks. 78 The study also recruited 74 age and sex-matched controls who were admitted to the same emergency departmeny for other reasons, of which 44 (59.5%) had received a BNT162b2 (Pfizer/ BioNTech) vaccine dose within the past four weeks. Following adjustment for previous history of peripheral nerve palsy, autoimmune disease, and diabetes, the multivariate odds ratio (OR) for the exposure to the vaccine among cases was not statistically significant (OR, 0.84; 95% CI 0.37 to 1.90; p=0.67), although it is noted that the study was limited by the modest sample size and potential for selection bias secondary to the hospital-based convenience sample. A large population-based nested case-control study reported that the age-standardised incidence of Bell's palsy was 66.9 cases per 100,000 person-years within 42 days following the inactivated virus CoronaVac (Sinovac) vaccine, and 428 per 100 000 person-years (19·4 to 66·1) within 42 days following the BNT162b2 vaccination. 79 The adjusted odds ratio for Bell's palsy was significant for CoronaVac (Sinovac) vaccine relative to the background population (OR, 2.385; 95% CI, 1.415 to 4.022) but not for the BNT162b2 (Pfizer/ BioNTech) vaccine (OR, 1.755; 95% CI, 0·886 to 3·477). Nevertheless, it is acknowledged that the observational design of the study precludes the inference of causality. Moreover, the pathophysiology of postvaccination Bell's palsy remains unclear, and hypothesised mechanisms include molecular mimicry, immune-mediated segmental demyelination, reactivation of latent herpes simplex type 1 infections in the geniculate ganglion, and/or bystander activation of dormant autoreactive T-cells. 79, 80 In conclusion, there has been limited research evaluating the potential ocular adverse effects of COVID-19 vaccines. A small number of case reports have documented the development of uveitis flares and acute corneal graft rejection within the first three weeks post-immunisation. In addition, rare instances of postvaccination optic neuropathies, retinal conditions, scleritis, and herpetic eye disease have also been highlighted, although it is acknowledged that causation and direct association cannot be inferred from isolated cases. Overall, data from populationbased pharmacovigilance reporting systems would suggest that ocular side effects are very rare following COVID-19 vaccination, and there is no substantive evidence to counterweigh the overwhelming benefits of immunisation in patients with preexisting ophthalmic conditions. However, it is acknowledged that it remains prudent to provide patient counselling to seek prompt medical review for symptoms of postvaccination visual decline or disease relapse. This narrative literature review summarizes the current evidence on COVID-19 vaccineassociated ocular adverse events. A small number of case reports have documented uveitis flares, acute corneal graft rejection, optic neuropathies, retinal conditions, and herpetic eye disease following immunisation. However, population-based pharmacovigilance data suggest that the prevalence of vaccination-associated ocular adverse events are very rare, and there is currently no substantive evidence to counterweigh the overwhelming benefits of COVID-19 immunisation in patients with pre-existing ophthalmic conditions. None. Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review Coronavirus Pandemic (COVID-19) Effect of the covid-19 pandemic in 2020 on life expectancy across populations in the USA and other high income countries: simulations of provisional mortality data SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 SARS-CoV-2 Vaccines Safety and Efficacy of the BNT162b2 mRNA Covid-19 Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Surveillance for Adverse Events After COVID-19 mRNA Vaccination Planning for COVID-19 vaccines safety surveillance Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study Myocarditis and Pericarditis After Vaccination for COVID-19 Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: Evaluation, management, and scientific questions Ocular Adverse Events After COVID-19 Vaccination World Health Organization (WHO) Programme for International Drug Monitoring Upsala: World Health Organization (WHO) Collaborating Centre for International Drug Monitoring Available from Australian Government Department of Health Available from Canada Vigilance adverse reaction database EudraVigilance: European database of suspected adverse drug reaction United Kingdom Department of Health and Social Care Available from Vaccine Adverse Event Reporting System (VAERS) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study Acute Uveitis following COVID-19 Vaccination Bilateral Multifocal Choroiditis following COVID-19 Vaccination Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association Panuveitis following Vaccination for COVID-19 Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination Association of Ocular Adverse Events With Inactivated COVID-19 Vaccination in Patients in Abu Dhabi Vaccine-Associated Uveitis Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series Ipsilateral Zoster Ophthalmicus Post COVID-19 Vaccine in Healthy Young Adults Reactivation of herpesvirus infections after vaccinations? Reactivation of herpes simplex keratitis following vaccination for COVID-19 Acute corneal endothelial graft rejection following COVID-19 vaccination Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine Corneal graft rejection following COVID-19 vaccine Corneal graft rejection after COVID-19 vaccination Keratoplasty Rejection After the BNT162b2 messenger RNA Vaccine Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence? Corneal Graft Rejection after Yellow Fever Vaccine: A Case Report Corneal allograft rejection following immunization Corneal transplant rejection following influenza vaccination COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses Alloimmunity and Tolerance in Corneal Transplantation Survey of Corneal Surgeons' Attitudes Regarding Keratoplasty Rejection Risk Associated With Vaccinations Bilateral Acute Macular Neuroretinopathy After Vaccination Against SARS-CoV-2 Acute macular neuroretinopathy following COVID-19 vaccination Acute Macular Neuroretinopathy following Coronavirus Disease 2019 Vaccination COVID-19 Recombinant mRNA Vaccines and Serious Ocular Inflammatory Side Effects: Real or Coincidence? Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2 Acute Thyroiditis and Bilateral Optic Neuritis following SARS-CoV-2 Vaccination with CoronaVac: A Case Report Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients Report: Postvaccination Anti-Myelin Oligodendrocyte Glycoprotein Neuromyelitis Optica Spectrum Disorder: A Case Report and Literature Review of Postvaccination Demyelination COVID-19-Induced Acute Bilateral Optic Neuritis Myelin oligodendrocyte glycoprotein antibodyassociated optic neuritis in a COVID-19 patient: A case report Optic Neuritis in a Patient with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody During the Post-COVID-19 Period Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: A study of 12 patients and a literature review A Rare Case of Superior Ophthalmic Vein Thrombosis and Thrombocytopenia Following ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2 Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia Acute abducens nerve palsy following COVID-19 vaccination Motor palsies of cranial nerves (excluding VII) after vaccination: reports to the US Vaccine Adverse Event Reporting System Benign recurrent sixth nerve palsies in childhood. Secondary to immunization or viral illness Benign Recurrent Sixth (Abducens) Nerve Palsy following Measles-Mumps-Rubella Vaccination Recurrent isolated sixth nerve palsy after consecutive annual influenza vaccinations in a child Isolated abducens nerve palsy following neonatal hepatitis B vaccination Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses Bell's palsy following COVID-19 vaccination Bell's Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine Bilateral Facial Nerve Palsy and COVID-19 Vaccination: Causation or Coincidence? Bell's palsy following a single dose of mRNA SARS-CoV-2 vaccine: a case report Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study Do Vaccines Have a Role as a Cause of Autoimmune Neurological Syndromes? He received his MBChB and PhD degrees from the University of Auckland, and has co-authored over 100 peer-reviewed publications in ophthalmology and internal medicine Danesh-Meyer is the Sir William and Lady Stevenson Professor of Ophthalmology and Head of Academic Neuro-ophthalmology and Glaucoma at the University of Auckland. She undertook both a Neuro-ophthalmology and Glaucoma Fellowship at Wills Eye Hospital in Philadelphia She has served as the Neuro-ophthalmology International Consultant for the Basic and Clinical Science Course (BCSC) for the American Academy of Ophthalmology (AAO) This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors have no conflicts of interest to declare.